ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor–Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy by Tomás Reinert, Tomás Reinert, Tomás Reinert, Susana Ramalho, Vivian Castro Antunes de Vasconcelos, Leonardo Roberto Silva, Ana Elisa Ribeiro da Silva, Camila Annicchino de Andrade, Maria Beatriz de Paula Leite Kraft, Guilherme Portela Coelho, Jovana Mandelli, Monique Binotto, Cesar Cabello, Geisilene Russano de Paiva Silva, José Bines, Carlos H. Barrios, Matthew J. Ellis, Marcia Silveira Graudenz

Get full text